



MINUTES

4th BioEscalator Genetic Modification Safety Committee Meeting held on Wednesday 11th November 2020, 10:00-11:00, MS Teams.

Present:

Khwaja Islam (Chair) (BioEscalator Biological Safety Officer)
Julie Hamilton (University Divisional Safety Officer)
Cathy Gouveia (MoA-Technology Ltd)
Loic Revuelta-Luis (Nucleome Therapeutics Ltd)
Kevin Maskell (Bioarchitech Ltd)
Ashling Holland (Pepgen Ltd)
John Hinks (Base genomics)
Kenny Moore (Ochre Bio Ltd)
Chris Willberg (Medimab Biotherapeutics Ltd)

1. Apologies:

Graham Ross (University Divisional Safety Officer) Len Seymour (University of Oxford) Matt Hayman (Theolytics Ltd)

2. Minutes of the last meeting:

Minutes approved by committee members.

3. Introduction of Member:

New members Kenny Moore, Chris Willberg, Loic Revuelta-Luis and John Hinks were introduced to the Committee.

4. Company Departure:

KI informed that Mirobio Ltd have left the BioEscalator on 30th June 2020 to Oxford Science Park and Metamorph Therapeutics Ltd on the 18th March 2020.

5. Update on CDA:

It was agreed in previous meeting that any new companies who want to do any GM work, would need to be added the CDA (a multi-way agreement between the companies) before any risk assessment could be circulated for approval by the committee. Ochre Bio, Medimab Biotherapeutics and base genomics will need to be added to the CDA. CG will amend the CDA once she receives the details of company name and registered address. Once CDA has been amended, it will need to be signed off by the new companies.

Action:

Email CG with company name and company registered address to add to the CDA.

6. Approval of Risk Assessments prior to the meeting:

KI reported two contained use activities (risk assessments) approved prior to the meeting as follows:

- a) 1 x class 2 (Ochre Bio Ltd)
- b) 1 X class 2 (Medimab Biotherapeutics Ltd)

7. Any Other Business (AOB):

JH is in the process of doing a risk assessment (RA) which he will circulate to the committee once it's completed. KI stated all approved and signed RA are kept in a folder (and on his drive) in the lab manager's office.

8. Date and venue of next meeting:

TBA for November 2021.